Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in first-line metastatic non-squamous non-small cell lung cancer
2015-003605-42Phase 3Active
- Sponsor
- Roche
- Start
- Feb 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, carboplatin, cisplatin and pemetrexed in Non-small cell lung cancer (NS-NSCLC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Feb 2016; status: active.
02
Drugs
atezolizumabcarboplatincisplatinpemetrexed
03
Conditions
Non-small cell lung cancer (NS-NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-003605-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003605-42.